2. Academic Validation
  3. Epigenetic modification-associated molecular classification of gastric cancer

Epigenetic modification-associated molecular classification of gastric cancer

  • Lab Invest. 2023 May 5;100170. doi: 10.1016/j.labinv.2023.100170.
Wei Zeng 1,  Jinfeng Zhu 2,  Dongqiang Zeng 3,  Jian Guo 3,  Genjie Huang 3,  Yu Zeng 3,  Ling Wang 3,  Jianping Bin 4,  Yulin Liao 4,  Min Shi 3,  Wangjun Liao 5
Affiliations

Affiliations

  • 1 Department of Oncology, First Peoples Hospital of Shunde: Shunde Hospital of Southern Medical University, 528300, Shunde, China; Department of Hematology and Oncology, Shenzhen University General Hospital, Shenzhen University, 518071, Shenzhen, China.
  • 2 Department of General Surgery, Shenzhen University General Hospital, Shenzhen University, 518071, Shenzhen, China.
  • 3 Department of Oncology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China; Guangdong Province Key Laboratory of Molecular Tumor Pathology, Southern Medical University, 510515, Guangzhou, China.
  • 4 Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China.
  • 5 Department of Oncology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China; Guangdong Province Key Laboratory of Molecular Tumor Pathology, Southern Medical University, 510515, Guangzhou, China. Electronic address: [email protected].
PMID: 37150296 DOI: 10.1016/j.labinv.2023.100170
Abstract

Epigenetic modification is involved in tumorigenesis and Cancer progression. We developed an epigenetic modification-associated molecular classification of gastric Cancer (GC) to identify signature genes that accurately predict prognosis and the efficacy of immunotherapy. Last absolute shrinkage and selection operator and multivariate COX regression analysis were conducted to develop an epigenetic modification-associated molecular classification. We investigated the significance of PIP4P2, an independent prognostic factor of the classification system, in predicting the prognosis and immunotherapy efficacy of GC patients. Epigenetic modification-associated molecular classification was highly associated with the clinicopathological characteristics of patients and the existing classification of GC. PIP4P2 was highly expressed in GC tissue and tumor-associated macrophages. High PIP4P2 expression in GC tissue induced tumor progression by activating PI3K/Akt signal transduction and had a negative impact on immunotherapy efficacy. High expression of PIP4P2 in macrophages was correlated with poor prognosis in GC patients. PIP4P2, as an independent unfavorable prognostic factor of epigenetic modification-associated molecular classification, is involved in tumorigenic progression and is essential for assessing the prognosis and immunotherapy efficacy of GC.

Keywords

PIP4P2 1; epigenetic modification 2; gastric cancer 3; immunotherapy efficacy 5; prognosis 4.

Figures
Products